Immix Biopharma (NASDAQ:IMMX - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.
IMMX has been the topic of a number of other research reports. HC Wainwright lifted their price target on shares of Immix Biopharma from $7.00 to $8.00 and gave the company a "buy" rating in a report on Friday, September 12th. Wall Street Zen downgraded shares of Immix Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 30th. Finally, Zacks Research downgraded shares of Immix Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 25th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $8.00.
Get Our Latest Research Report on IMMX
Immix Biopharma Stock Performance
Shares of NASDAQ IMMX opened at $2.54 on Wednesday. Immix Biopharma has a 1 year low of $1.34 and a 1 year high of $3.20. The firm's 50 day moving average price is $2.24 and its 200 day moving average price is $2.18. The firm has a market cap of $73.24 million, a P/E ratio of -3.30 and a beta of 0.23.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.01). As a group, equities analysts predict that Immix Biopharma will post -0.87 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Immix Biopharma stock. Tritonpoint Wealth LLC bought a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 24,526 shares of the company's stock, valued at approximately $51,000. Tritonpoint Wealth LLC owned about 0.09% of Immix Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 11.26% of the company's stock.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
